Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Pembrolizumab

Latent hyperthyroidism, immune-related hypothyroidism and hyperthyroidism

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Haas M, et al. Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab. International Immunopharmacology 123: Aug 2023. Available from: URL: 10.1016/j.intimp.2023.110799 Haas M, et al. Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab. International Immunopharmacology 123: Aug 2023. Available from: URL: 10.1016/j.intimp.2023.110799
Metadaten
Titel
Pembrolizumab
Latent hyperthyroidism, immune-related hypothyroidism and hyperthyroidism
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56517-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs